Pediatric brain tumors are the most common cancer and cause of cancer death in children, emphasizing the need for innovative treatment strategies (ref: Price doi.org/10.1093/neuonc/).
Transcriptomics-guided drug screening identified SN-38 as a potential therapy for DIPG, showcasing the importance of personalized medicine (ref: Jiang doi.org/10.1093/neuonc/).
Germline variants in gliomas highlight the genetic predispositions that inform treatment strategies in pediatric populations (ref: Nandakumar doi.org/10.1007/s00401-025-02935-x/).
Minimally invasive surgical techniques have limited eligibility, with only 2% to 4% of ICH patients qualifying for such procedures (ref: Wechsler doi.org/10.1161/STROKEAHA.125.052998/).
The meta-analysis on anticoagulation resumption after ICH revealed a recurrent ICH rate of 11.4%, highlighting the risks involved (ref: D'Anna doi.org/10.1212/WNL.0000000000214184/).
Innovative therapies, such as gene therapy for Canavan disease, demonstrate the potential for targeted interventions in pediatric neurosurgery (ref: Leone doi.org/10.1038/s41591-025-03919-w/).
Epidemiological insights into pediatric brain tumors underscore the need for public health initiatives aimed at early detection and intervention (ref: Price doi.org/10.1093/neuonc/).